FDA approves first biosimilar to Neulasta to help reduce the risk of infection during cancer treatment

Author(s):  
2021 ◽  
pp. 2-2
Author(s):  
Mariia Pavlushenko ◽  
Roman Liubota ◽  
Roman Vereshchako ◽  
Nikolay Anikusko ◽  
Irina Liubota

The biggest challenge for the World Health Organization today is the fight against the COVID-19 pandemic. The current situation prompted major adjustments in the system of cancer care. In this review, we investigate the aspects of cancer treatment and care during the pandemic, since in this setting oncological services face challenges in determining the feasibility of anticancer treatments while minimizing the risk of infection. Cancer patients are at a higher risk from COVID-19 disease. Therefore, oncological community is discussing on the priorities for providing cancer therapies and care and at the same time minimizing the risk of infection.


2020 ◽  
Vol 2 (3) ◽  
Author(s):  
Nagwa Ibrahim ◽  
Mohamed Almeziny ◽  
Abdulaziz Alhamad ◽  
Ashraf Farrag

The COVID-19 pandemic led to several critical challenges that impacted the healthcare system worldwide. Many guidelines have been developed internationally and nationally aiming to minimize the risk of infection and its sequential complications. Cancer patients on active treatment are at higher risk to get infected either due to the disease itself or the cancer treatment and other comorbid diseases. In this manuscript we share our local experience while delivering oncology services during the COVID-19 pandemic at Prince Sultan Military Medical City in Riyadh, Saudi Arabia.


2013 ◽  
Vol 60 (8) ◽  
pp. 1307-1312 ◽  
Author(s):  
Margareta af Sandeberg ◽  
Lena Wettergren ◽  
Olle Björk ◽  
Johan Arvidson ◽  
Eva Johansson

2004 ◽  
Vol 171 (4S) ◽  
pp. 284-284
Author(s):  
Yi Lu ◽  
Jun Zhang ◽  
Ben Beheshti ◽  
Ximing J. Yang ◽  
Syamal K. Bhattacharya ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document